LABP vs. ASMB, LTRN, SCYX, DERM, VHAQ, YS, RLYB, IFRX, MNOV, and MURA
Should you be buying Landos Biopharma stock or one of its competitors? The main competitors of Landos Biopharma include Assembly Biosciences (ASMB), Lantern Pharma (LTRN), SCYNEXIS (SCYX), Journey Medical (DERM), Viveon Health Acquisition (VHAQ), YS Biopharma (YS), Rallybio (RLYB), InflaRx (IFRX), MediciNova (MNOV), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical preparations" industry.
Landos Biopharma (NASDAQ:LABP) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
Landos Biopharma has higher revenue and earnings than Assembly Biosciences.
Landos Biopharma's return on equity of -66.00% beat Assembly Biosciences' return on equity.
Assembly Biosciences received 212 more outperform votes than Landos Biopharma when rated by MarketBeat users. However, 62.50% of users gave Landos Biopharma an outperform vote while only 59.31% of users gave Assembly Biosciences an outperform vote.
In the previous week, Assembly Biosciences had 31 more articles in the media than Landos Biopharma. MarketBeat recorded 35 mentions for Assembly Biosciences and 4 mentions for Landos Biopharma. Assembly Biosciences' average media sentiment score of 0.15 beat Landos Biopharma's score of -0.76 indicating that Assembly Biosciences is being referred to more favorably in the news media.
Landos Biopharma currently has a consensus price target of $20.42, indicating a potential downside of 8.55%. Given Landos Biopharma's higher possible upside, research analysts plainly believe Landos Biopharma is more favorable than Assembly Biosciences.
49.1% of Landos Biopharma shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 1.3% of Landos Biopharma shares are owned by insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Landos Biopharma has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.
Summary
Assembly Biosciences beats Landos Biopharma on 7 of the 13 factors compared between the two stocks.
Get Landos Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landos Biopharma Competitors List
Related Companies and Tools
